Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme

OBJECTIVES: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). To further assess the potential role of Janus kinase inhibition in the development of malignancies, we performed an integrated analysis of data from the tofacitinib RA clinical development progr...

Descripción completa

Detalles Bibliográficos
Autores principales: Curtis, Jeffrey R, Lee, Eun Bong, Kaplan, Irina V, Kwok, Kenneth, Geier, Jamie, Benda, Birgitta, Soma, Koshika, Wang, Lisy, Riese, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4853586/
https://www.ncbi.nlm.nih.gov/pubmed/25902789
http://dx.doi.org/10.1136/annrheumdis-2014-205847

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4853586/
https://www.ncbi.nlm.nih.gov/pubmed/25902789
http://dx.doi.org/10.1136/annrheumdis-2014-205847

Ejemplares similares